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ABSTRACT
Objectives Men who have sex with men (MSM) 
have an increased risk of human papillomavirus (HPV) 
infection and related diseases compared with men who 
have sex exclusively with women. From April 2018, there 
has been a phased roll- out of HPV vaccination offered to 
MSM aged up to 45 years old who are attending sexual 
health clinics and HIV clinics in England. The vaccine 
is most effective if delivered prior to HPV infection. 
We estimated the proportion of MSM with no current 
vaccine- type infection and no serological evidence of 
prior infection, in a study undertaken prior to vaccine 
introduction.
Methods We conducted a cross- sectional study among 
484 MSM aged 18–40 years old who attended a sexual 
health clinic in London between 2010 and 2012. We 
estimated the prevalence of current and past infection 
by testing for HPV DNA in anogenital samples and for 
serum antibodies to HPV16 and HPV18.
Results The median age was 30 years (IQR 25–35). 
The prevalence of HPV16 and HPV18 DNA was 13.2% 
and 6.2%, respectively. Seropositivity for HPV16 and 
HPV18 was 28.5% and 17.1%, respectively, with 11.4% 
seropositive for both types. Seropositivity for the same 
HPV type was strongly associated with anogenital DNA 
detection. 279 MSM (57.6%) tested negative for both 
HPV16 and HPV18 serology and were DNA negative for 
these two types; only 5 MSM (1.0%) were seropositive 
and DNA positive for both HPV types.
Conclusions This is the first study to determine both 
the prevalence of HPV DNA in anogenital samples and 
HPV seroprevalence among MSM attending a sexual 
health clinic in the UK. Over half of MSM in this study 
had no evidence of a previous or current infection 
with either of the high- risk HPV types included in the 
quadrivalent vaccine, which supports the rationale for 
opportunistic HPV vaccination of MSM attending sexual 
health clinics.
INTRODUCTION
In the UK, the National Human Papillomavirus 
(HPV) Immunisation Programme was introduced in 
2008 for girls aged 12–13 years, with a catch- up 
programme up to 18 years old. Initially the biva-
lent vaccine was used, which protects against two 
of the high- risk types, HPV16 and HPV18, associ-
ated with cancers of the cervix, vulva, vagina, anus, 
penis and oropharynx.1 Since 2012, the national 
programme has used the quadrivalent vaccine, 
which protects against HPV16 and HPV18, as well 
as the low- risk types HPV6 and HPV11, which are 
responsible for the vast majority of genital warts.2 
The vaccines are prophylactic and hence are most 
effective if given prior to exposure to HPV infec-
tion. The presence of a current HPV infection is 
evidenced by detectable HPV DNA. Not all indi-
viduals who have a natural infection will serocon-
vert for that HPV type. However, where there is 
serological evidence of HPV infection, this could 
indicate either a current infection or past infection. 
Both HPV DNA infection and HPV seropositivity 
for vaccine types can reduce the efficacy of vaccina-
tion.3 Therefore, it is important to understand the 
HPV DNA prevalence and HPV seroprevalence of 
a population prior to recommending a vaccination 
strategy. Serological studies directly contributed to 
the cost- effectiveness modelling that informed the 
introduction of female HPV vaccination in the UK.4 
The high coverage achieved in the female vaccina-
tion programme in the UK has been shown to have 
a substantial impact on the prevalence of vaccine- 
type HPV infection in women in England5 and Scot-
land.6 Furthermore, data from England, Australia 
and elsewhere suggest a herd protection effect, with 
a decline in the incidence of genital warts among 
young women and heterosexual men.7–10 However, 
men who have sex with men (MSM) are likely to 
have little or no herd protection from vaccinating 
only women and will continue to have a high risk of 
HPV infection and related diseases.11 12
We have previously published data on the preva-
lence of current HPV infection, determined by HPV 
DNA detection, among MSM attending a London 
sexual health clinic.11 These data informed the 
mathematical models used to estimate the impact 
and cost- effectiveness of HPV vaccination of MSM 
in England.13 Subsequently, in November 2015, the 
Joint Committee on Vaccination and Immunisation 
advised that a targeted programme of HPV vacci-
nation for MSM aged up to 45 years old attending 
specialist sexual health services or HIV clinics in the 
UK should be introduced, if it could be delivered 
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cost- effectively.14 Following this advice, a pilot programme was 
implemented in 42 clinics across England, with the first clinic 
starting vaccination in June 2016. Following the success of the 
pilot, it was announced that there would be a phased national 
roll- out of the programme from April 2018. The impact of vacci-
nation of MSM on rates of HPV infection and related diseases 
will depend on the proportion of eligible MSM with a current 
or previous HPV infection. We present here HPV16 and HPV18 
seroprevalence in the same population of MSM to better esti-
mate the potential benefit of vaccination in this setting.
METHODS
We conducted a cross- sectional survey including men aged 18–40 
years old who reported anal or oral sex with another man in the 
last 5 years and who attended the Mortimer Market Centre in 
London between October 2010 and July 2012. Participants were 
asked to complete a computer- assisted self- interview question-
naire which included demographics, sexual behaviour, history 
of STIs, knowledge of HPV and attitudes towards HPV vaccina-
tion. At the same visit, specimens were collected for HPV DNA 
testing. Full details of sampling and HPV DNA testing have been 
previously published.11 In brief, two swabs were taken, one anal 
and one from the glans of the penis/coronal sulcus, penile shaft, 
scrotum and perianal area (external genital). Specimens were 
tested for type- specific HPV DNA using an inhouse multiplex 
PCR and Luminex- based genotyping test to detect 20 HPV types 
(high- risk types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 
68; possible high- risk types: 26, 53, 70, 73, 82; and low- risk 
types: 6, 11).
A blood sample was also taken at the same time as the genital 
specimens and used to produce two aliquots of serum stored 
at −20°C before transportation on dry ice to Public Health 
England Vaccine Evaluation Unit, Manchester. Serum specimens 
were tested for IgG to HPV16 and HPV18 using a type- specific 
ELISA as described previously.15 Results are expressed as ELISA 
units per millilitre (EU/mL) by reference to a standard, with cut- 
offs for detection of 19 and 18 EU/mL for HPV16 and HPV18, 
respectively.
The association between type- specific HPV DNA detection 
(at any anogenital site) and HPV seropositivity was explored 
using logistic regression. This analysis was performed separately 
for HPV16 and HPV18. Regression analyses were adjusted for 
demographic and sexual behaviour variables which potentially 
confounded the association between HPV DNA detection and 
HPV seropositivity (the final model for both HPV types was 
adjusted for by age and lifetime number of male sexual partners, 
categorised as <20 men, 21–30 men, 31–100 men, 101–500 
men and more than 500 men).
RESULTS
A total of 522 MSM participated in the study. These analyses are 
restricted to the 484 (92.7%) MSM with at least one adequate 
anal/external genital swab and a blood sample. The median age 
was 30 years (IQR 25–35). Demographic and behavioural char-
acteristics of study participants are shown in table 1. The preva-
lence of high- risk HPV DNA detection in anogenital swabs was 
47.3% (n=229; 95% CI 42.9% to 51.8%). HPV16 and HPV18 
prevalence was 13.2% (95% CI 10.5% to 16.6%) and 6.2% 
(95% CI 4.4% to 8.7%), respectively; 1.5% (95% CI 0.7% to 
3.0%) of MSM were HPV DNA positive for both HPV16 and 
HPV18. Full details of the HPV DNA prevalence data have been 
previously published.11
The concordance between HPV DNA detection and type- 
specific seropositivity is shown in table 2 and figure 1. Of the 
484 participants, 28.5% (n=138) were seropositive for HPV16, 
17.1% (n=83) for HPV18 and 11.4% (n=55) seropositive for 
both HPV types. Around two- thirds of MSM (n=318; 65.7%) 
were seronegative for both HPV16 and HPV18.
Of the 138 MSM who were seropositive for HPV16, 37 
(26.8%) had concurrent HPV16 DNA detected and only 12 
(8.7%) had HPV18 DNA detected (table 2). Seropositivity for 
HPV16 was associated with anogenital HPV16 DNA detec-
tion (OR 4.33; 95% CI 2.51 to 7.46). Similarly, of 83 MSM 
who were seropositive for HPV18, 12 (14.4%) had concurrent 
HPV18 DNA detected while 17 (20.5%) had HPV16 DNA 
detected (table 2). Seropositivity for HPV18 was also associated 
with anogenital HPV18 DNA detection (OR 3.60; 95% CI 1.66 
Table 1 Patient characteristics and sexual behaviour among MSM 




  18–20 16 (3.3)
  21–25 114 (23.6)
  26–30 122 (25.2)
  31–35 134 (27.7)
  36–40 98 (20.3)
Ethnicity
  White 358 (76.7)
  Black 28 (6)
  Asian and South- East Asian 34 (7.3)
  Mixed/other 47 (10.1)
Country of birth
  UK 220 (46.8)
  Outside of UK 250 (53.2)
Smoker
  No 330 (70.4)
  Yes 139 (29.6)
Alcohol use†
  No- risk drinking 162 (34.8)
  Risk drinking 303 (65.2)
Currently employed
  No 102 (21.7)
  Yes 368 (78.3)
Years of education since 16 years of age
  None 12 (2.6)
  Up to 2 years 57 (12.1)
  3 years or more 319 (67.9)
  Currently studying 82 (17.5)
Sexual orientation
  Straight/heterosexual 0 (0)
  Gay/homosexual 427 (91)
  Bisexual 42 (9)
Total lifetime male sex partners*
  ≤30 161 (34.3)
  31–100 161 (34.3)
  101–500 148 (31.5)
HIV- positive
  No 459 (94.8)
  Yes 25 (5.2)
*Includes oral and anal partners.
†Alcohol use disorders identification test (AUDIT- C)
MSM, men who have sex with men.
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to 7.79). Only five MSM (1.0%) were both seropositive for both 
HPV16 and HPV18 and DNA positive for both viruses.
No evidence of either current or past HPV16 or HPV18 infec-
tion was found in 57.6% of MSM (n=279).
DISCUSSION
We present the results of tests for serum HPV antibody against 
two high- risk HPV types in a population of MSM attending a 
London sexual health clinic who were also tested for anogen-
ital HPV DNA. Compared with data on HPV DNA prevalence 
alone, this provides a more precise estimate of the potential 
benefit of vaccinating this population. Over half of the MSM 
had no evidence of either a previous or current HPV16 or 
HPV18 infection, based on the results of both HPV DNA and 
serology. Around one- third (35.0%) had antibody to either or 
both HPV types, and a further 8.2% had detectable HPV DNA 
but negative serology.
This is the first study to relate the prevalence of HPV DNA 
and HPV type- specific antibody among MSM in England, and 
importantly was conducted among sexual health clinic attenders 
who would now be eligible to receive the HPV vaccine. A major 
strength of the study was that we compared HPV DNA prev-
alence at multiple genital sites with HPV seroprevalence using 
samples collected at the same time. We found that the majority 
of seropositive MSM were DNA negative for the same HPV 
type, suggesting that they either had an infection which was 
undetected at the time or they had a previous HPV infection 
that was cleared.
Not all men will seroconvert following a natural infection 
with an HPV type, although studies of HPV seroprevalence 
among MSM16–18 have demonstrated that this is higher than 
seroprevalence among men who have sex with women.17 19 20 
This is likely in part to be due to higher risk sexual behaviour 
and in part due to the site of infection, with evidence that infec-
tion of the mucosal epithelium of the anal canal may be more 
likely to induce an antibody response, compared with infection 
of the external genitalia, which usually involves keratinised squa-
mous epithelium. This is supported by the observation that HPV 
seropositivity was associated with anal HPV infection, but not 
external genital infection.18 21 22
HPV vaccines are licensed for prophylaxis, but not for therapy 
of existing infections, and it has been shown that men with no 
current HPV infection but who are seropositive for an HPV type 
at the time of vaccination have a reduced vaccine efficacy against 
that specific type compared with those who are seronegative.3 
However, MSM with evidence of present or past infection with 
some, but not all, vaccine- type HPV infections still could benefit 
from vaccination to protect against those types that they have 
not already been infected with, particularly if their risk of HPV 
infection remains high. It is not clear whether vaccination of 
those with a prior infection has an impact on reinfection with 
the same HPV type, although there is evidence to suggest that the 
immune response to natural infection differs in both specificity 
and B cell memory from that induced by vaccination.23 24 A study 
in patients with genital warts, caused by low- risk HPV types, has 
provided some evidence for an effect on both wart clearance 
and reduction in wart recurrence, but in this randomised trial 
the CIs were wide and the differences did not reach statistical 
significance.25
The HPV DNA prevalence data included in this paper 
have been published previously.11 There are several published 
reports on the prevalence of HPV infection among MSM in 
different countries. Two systematic reviews, one considering 
anal infection and one oral infection, found an association 
between HPV infection in MSM and HIV seropositivity.26 27
It is plausible that MSM not attending a sexual health clinic 
could have a lower risk of HPV infection, or conversely MSM 
with limited access to healthcare may have a higher risk of infec-
tion and related diseases. The heterogeneity of HPV DNA prev-
alence and seroprevalence in different settings and countries 
highlights the importance of determining this in MSM attending 
sexual health clinics where vaccination may be offered. MSM 
included in our study were attending a large London- based 
sexual health clinic and reported high levels of sexual risk behav-
iour; around two- thirds of men had had more than 30 lifetime 
male sex partners and over 80% of men have more than 20 
male sex partners. MSM in this study may therefore be at higher 
risk of HPV infection than MSM attending some other clinics, 
or those not attending other health services, such as primary 
care. The proportion of MSM with no evidence of a current or 











Seronegative for both HPV16 and HPV18 279 (57.6) 25 (5.2) 13 (2.7) 1 (0.2)
HPV16 seropositive and HPV18 seronegative 58 (12.0) 21 (4.3) 4 (0.8) 0 (0.0)
HPV16 seronegative and HPV18 seropositive 24 (5.0) 0 (0.0) 3 (0.6) 1 (0.2)
Seropositive for both HPV16 and HPV18 36 (7.4) 11 (2.3) 3 (0.6) 5 (1.0)
Total 397 57 23 7
Number in brackets represents percentage of the total eligible samples (N=484).
Grey shaded cells are the numbers with fully concordant serology and HPV DNA detection results.
HPV, human papillomavirus; MSM, men who have sex with men.
Figure 1 HPV DNA infection and HPV seropositivity among 484 men who have sex with men. HPV, human papillomavirus.
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previous HPV infection may therefore be a minimum estimate 
of those likely to benefit from vaccination. However, one limi-
tation of this study was the relatively low number of MSM who 
were known to be HIV- positive, who have a higher prevalence of 
HPV DNA and HPV seropositivity. Another limitation was that 
we did not have sufficient power to compare seropositivity rates 
with prevalent HPV infection at specific anatomical sites.
The data on the prevalence of HPV DNA infection have 
informed the mathematical models used to estimate the 
impact and cost- effectiveness of HPV vaccination of MSM 
in England.13 These models, along with the data on the rela-
tionship between seropositivity and DNA detection, may be 
of interest to other countries considering implementation of a 
targeted MSM vaccination programme. In the UK, it has subse-
quently been decided to extend HPV vaccination to adolescent 
men as part of the National HPV Immunisation Programme. 
Routine vaccination will be offered to boys aged 12–13 years 
in a school- based programme, as for the girls. Over time this 
will start to impact on HPV infection rates in MSM, but this 
will take decades to substantially benefit the majority of MSM. 
There is still expected to be continued benefit in having a 
targeted MSM programme to reduce rates in older MSM and 
those who missed getting vaccinated in school or who have 
moved to the UK after age 13.
These data provide information on the proportion of men 
attending sexual health clinics who are likely to benefit from 
vaccination. It is encouraging that, in our study, the majority of 
MSM aged 18–40 years old have no detectable HPV DNA and 
no serological evidence of exposure to HPV infection despite 
reporting high rates of sexual risk behaviours. This supports the 
rationale for opportunistic HPV vaccination of MSM attending 
sexual health clinics.
Key messages
 ► From April 2018, human papillomavirus (HPV) vaccination 
has been offered to men who have sex with men (MSM) 
aged up to 45 years old attending sexual health clinics and 
HIV clinics in England.
 ► We present the results from a cross- sectional study including 
484 MSM aged 18–40 years old attending a sexual health 
clinic in London between 2010 and 2012.
 ► HPV16 and HPV18 DNA prevalence was 13.2% and 6.2%, 
respectively.
 ► Seropositivity for HPV16 and HPV18 was 28.5% and 17.1%, 
respectively; 11.4% seropositive for both types.
 ► Over half of the MSM in this study had no evidence of a 
previous or current infection with either HPV16 or HPV18.
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